Marinus Pharmaceuticals, Inc. offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome.
Market Cap | 332.629 Million | Shares Outstanding | 47.723 Million | Avg 30-day Volume | 461.441 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | 1.93 |
Price to Revenue | 6.1037 | Debt to Equity | 0.621 | EBITDA | -114.455 Million |
Price to Book Value | 1.389 | Operating Margin | -442.68780000000004 | Enterprise Value | -8.961 Million |
Current Ratio | 10.088 | EPS Growth | 0.81 | Quick Ratio | 9.869 |
1 Yr BETA | 1.2859 | 52-week High/Low | 10.29 / 3.47 | Profit Margin | -77.7769 |
Operating Cash Flow Growth | -103.4825 | Altman Z-Score | -1.9914 | Free Cash Flow to Firm | -55.071 Million |
Earnings Report | 2023-05-11 |
Please sign in first
none
2.8 Thousand total shares from 3 transactions
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
5,600 | 2023-02-06 | 2 | |
|
6,026 | 2023-02-06 | 2 | |
|
5,277 | 2023-02-06 | 2 | |
MANNING MARTHA E VP, GEN. COUNSEL & CORP. SEC. |
|
109,673 | 2023-01-26 | 2 |
|
33,675 | 2023-01-26 | 1 | |
BRAUNSTEIN SCOTT CHAIRMAN AND CEO |
|
527,205 | 2023-01-26 | 2 |
|
0 | 2023-01-26 | 2 | |
HULIHAN JOSEPH CHIEF MEDICAL OFFICER |
|
165,934 | 2023-01-26 | 2 |
|
22,550 | 2023-01-26 | 1 | |
PFANSTIEL STEVEN CHIEF FINANCIAL OFFICER |
|
178,713 | 2023-01-26 | 2 |
SHAFER CHRISTINA CHIEF COMMERCIAL OFFICER |
|
121,210 | 2023-01-26 | 3 |
|
15,687 | 2022-02-04 | 0 | |
|
18,817 | 2022-02-04 | 0 | |
|
15,125 | 2022-02-04 | 0 | |
SMITH EDWARD F FORMER VP, CFO & TREASURER |
|
No longer subject to file | 2021-03-09 | 0 |
|
0 | 2021-01-15 | 0 | |
LORIANNE MASUOKA K. CHIEF MEDICAL OFFICER |
|
0 | 2019-08-21 | 0 |
|
No longer subject to file | 2019-03-18 | 0 | |
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC BAIN CAPITAL LIFE SCIENCES PARTNERS, LP BAIN CAPITAL LIFE SCIENCES FUND, L.P. |
|
No longer subject to file | 2017-12-15 | 0 |
|
0 | 2017-01-17 | 0 | |
SOFINNOVA VENTURE PARTNERS VI L P SOFINNOVA VENTURE PARTNERS VI GMBH & CO. KG SOFINNOVA VENTURE AFFILIATES VI LP |
|
No longer subject to file | 2016-10-20 | 0 |
|
No longer subject to file | 2016-08-05 | 0 | |
|
0 | 2016-08-03 | 0 | |
PATRONEVA ALBENA CHIEF MEDICAL OFFICER |
|
0 | 2016-08-03 | 0 |
|
4,337,346 | 2015-09-24 | 0 | |
FARFEL GAIL M CHIEF CLINICAL DEV & REG OFFIC |
|
8,462 | 2015-04-21 | 0 |
|
42,550 | 2015-01-01 | 0 | |
|
0 | 2014-09-30 | 0 | |
|
2,476,886 | 2014-08-05 | 0 | |
|
17,000 | 2014-08-05 | 0 | |
|
42,550 | 2014-07-31 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-02-08 16:36:05 -0500 | 2023-02-06 | S | 1,073 | $6.49 | d | 5,277 | direct | yes | -4.1899 | 0.419 | -13.4078 | 3.5615 | 19 | -16.2011 | 29 | |
2023-02-08 16:37:47 -0500 | 2023-02-06 | S | 1,018 | $6.54 | d | 6,026 | direct | yes | -4.1899 | 0.419 | -13.4078 | 3.5615 | 19 | -16.2011 | 29 | |
2023-02-08 16:36:40 -0500 | 2023-02-06 | S | 750 | $6.56 | d | 5,600 | direct | yes | -4.1899 | 0.419 | -13.4078 | 3.5615 | 19 | -16.2011 | 29 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-30 19:15:05 UTC | 3.5502 | 1.2698 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-30 18:45:04 UTC | 3.5502 | 1.2698 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-30 18:15:04 UTC | 3.5502 | 1.2698 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-30 17:45:04 UTC | 3.5502 | 1.2698 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-30 17:15:04 UTC | 3.5502 | 1.2698 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-30 16:45:03 UTC | 3.4578 | 1.3622 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-30 16:15:04 UTC | 3.4578 | 1.3622 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-30 15:45:04 UTC | 3.4578 | 1.3622 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-30 15:15:04 UTC | 3.4578 | 1.3622 | 700000 |
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-30 14:45:03 UTC | 3.4578 | 1.3622 | 700000 |
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-30 14:15:04 UTC | 3.4578 | 1.3622 | 700000 |
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-30 13:45:04 UTC | 3.5659 | 1.2541 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-30 13:15:04 UTC | 3.5659 | 1.2541 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-30 12:45:04 UTC | 3.5659 | 1.2541 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-29 22:15:04 UTC | 3.5659 | 1.2541 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-29 21:45:05 UTC | 3.5659 | 1.2541 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-29 21:15:04 UTC | 3.5659 | 1.2541 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-29 20:45:06 UTC | 3.5659 | 1.2541 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-29 20:15:05 UTC | 3.5659 | 1.2541 | 650000 |
MARINUS PHARMACEUTICALS INC MRNS | 2023-03-29 19:45:05 UTC | 3.5659 | 1.2541 | 650000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
AQR Funds- AQR Small Cap Relaxed Constraint Equity Fund | MRNS | -1779.0 shares, $-2739.66 | 2019-09-30 | N-PORT |
Prudential Investment Portfolios 12- PGIM QMA Long-Short Equity Fund | MRNS | -1400.0 shares, $-15932.0 | 2021-09-30 | N-PORT |